Tumor specific monoclonal antibodies

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S388850, C530S391300, C530S391700, C424S130100, C424S133100, C424S156100, C424S178100, C424S183100

Reexamination Certificate

active

07115716

ABSTRACT:
The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.

REFERENCES:
patent: 6787638 (2004-09-01), Watkins et al.
Rudikoff et al. Proc. Natl. Acad. Sci. USA (1982) vol. 79. p. 1979.
Pancook et al (Hybridoma and Hybridomics, 20, Nov. 6, 2001 pp. 383-396).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Tumor specific monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor specific monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor specific monoclonal antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3667711

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.